The research presented at the ESMO Annual Meeting 2023 highlights the advantages of combining immunotherapy with chemotherapy in advanced or recurrent endometrial cancer. Two trials, AtTEnd and DUO-E, demonstrated improved progression-free survival (PFS) with the addition of immunotherapy. The AtTEnd trial focused on atezolizumab, showing significant PFS benefits, especially in patients with mismatch repair-deficient (dMMR) disease. The DUO-E trial explored the combination of durvalumab and olaparib with chemotherapy, also leading to improved PFS, particularly in dMMR patients. The studies suggest a positive impact on women with gynecological cancers, emphasizing the incorporation of immunotherapy into standard care.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Liam Davenpo... at www.medscape.com 10-22-2023
https://www.medscape.com/viewarticle/997607Deeper Inquiries